All In Biotech

Drug Trial Radar · NCT03078738

Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects

A First-in-Human Randomized, Double-blind, Placebo-controlled, Fed-fasted, Gender, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMT-28 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Feb 8, 2017

Primary completion

Mar 12, 2018

Study completion Mar 12, 2018

Sponsor

Lead sponsor
Omeicos Therapeutics GmbHIndustry
Sponsor type
Industry
First posted
Mar 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this first-in-human study is to assess the safety, tolerability, PK and exploratory pharmacodynamics (PD) of single and multiple oral ascending doses of OMT-28 in healthy male subjects to support further clinical development of OMT-28 in the indication of atrial fibrillation (AF) and to obtain data on food and gender effects of OMT-28 to guide dosing for Phase II trials.

Conditions

  • Healthy Volunteers

Interventions

  • OMT-28Drug

    OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).

  • Matching PlaceboOther

    Microcrystalline cellulose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety assessed by frequency and nature of treatment-emergent adverse eventsTime frame: From Day 1 to Day 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRS-Mönchengladbach

    Mönchengladbach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.